» Articles » PMID: 32025725

Imaging Growth As a Predictor of Grade of Malignancy and Aggressiveness of IDH-mutant and 1p/19q-codeleted Oligodendrogliomas in Adults

Abstract

Background: We quantified the spontaneous imaging growth rate of oligodendrogliomas. We assessed whether (i) it discriminates between World Health Organization (WHO) grade II and grade III oligodendrogliomas, and (ii) grade III oligodendrogliomas with neo-angiogenesis are associated with more fast growth rates (≥8 mm/y).

Methods: This work employed a retrospective bicentric cohort study (2010-2016) of adult patients harboring a newly diagnosed supratentorial oligodendroglioma, isocitrate dehydrogenase (IDH) mutant and 1p/19q codeleted (WHO 2016 classification), with a minimum of 2 available MRIs before any treatment (minimum 6-week interval) to measure the spontaneous tumor growth rate.

Results: We included 108 patients (age 44.7 ± 14.1 y, 60 males). The tumor growth rate was higher in grade III oligodendrogliomas with neo-angiogenesis (n = 37, median 10.4 mm/y, mean 10.0 ± 6.9) than in grade III oligodendrogliomas with increased mitosis count only (cutoff ≥6 mitoses, n = 18, median 3.9 mm/y, mean 4.5 ± 3.2; P = 0.004), and higher than in grade II oligodendrogliomas (n = 53, median 2.3 mm/y, mean 2.8 ± 2.2; P < 0.001). There was increased prevalence of fast tumor growth rates in grade III oligodendrogliomas with neo-angiogenesis (54.1%) compared with grade III oligodendrogliomas with increased mitosis count only (11.1%; P < 0.001), and in grade II oligodendrogliomas (0.0%; P < 0.001). The tumor growth rate trends did not differ between centers (P = 0.121). Neo-angiogenesis (P < 0.001) and mitosis count at ≥9 (P = 0.013) were independently associated with tumor growth rates ≥8 mm/year. A tumor growth rate ≥8 mm/year was the only predictor independently associated with shorter progression-free survival (P = 0.041).

Conclusions: The spontaneous tumor growth rate recapitulates oligodendroglioma aggressiveness, permits identification of grade III oligodendrogliomas preoperatively when ≥8 mm/year, and questions the grading by mitosis count.

Citing Articles

Who will benefit from vorasidenib? Review of data from the literature and open questions.

Darlix A, Preusser M, Hervey-Jumper S, Shih H, Mandonnet E, Taylor J Neurooncol Pract. 2025; 12(Suppl 1):i6-i18.

PMID: 39776530 PMC: 11703370. DOI: 10.1093/nop/npae104.


The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?.

van den Bent M, French P, Brat D, Tonn J, Touat M, Ellingson B Neuro Oncol. 2024; 26(10):1805-1822.

PMID: 38912846 PMC: 11449017. DOI: 10.1093/neuonc/noae107.


Tumor volume and calcifications as indicators for preoperative differentiation of grade II/III diffuse gliomas.

Fukuya Y, Tamura M, Nitta M, Saito T, Tsuzuki S, Koriyama S J Neurooncol. 2023; 161(3):555-562.

PMID: 36749444 DOI: 10.1007/s11060-023-04244-3.


2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist.

McNamara C, Mankad K, Thust S, Dixon L, Limback-Stanic C, DArco F Neuroradiology. 2022; 64(10):1919-1950.

PMID: 35869291 DOI: 10.1007/s00234-022-03008-6.


Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.

Garnier L, Vidal C, Chinot O, Moyal E, Djelad A, Bronnimann C Oncologist. 2022; 27(5):414-423.

PMID: 35522558 PMC: 9074983. DOI: 10.1093/oncolo/oyac023.


References
1.
Hlaihel C, Guilloton L, Guyotat J, Streichenberger N, Honnorat J, Cotton F . Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas. J Neurooncol. 2009; 97(1):73-80. DOI: 10.1007/s11060-009-9991-4. View

2.
Mandonnet E, Pallud J, Fontaine D, Taillandier L, Bauchet L, Peruzzi P . Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev. 2009; 33(1):91-6. DOI: 10.1007/s10143-009-0229-x. View

3.
Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J . Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2012; 31(3):337-43. PMC: 3732012. DOI: 10.1200/JCO.2012.43.2674. View

4.
Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P . Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002; 20(8):2076-84. DOI: 10.1200/JCO.2002.08.121. View

5.
Dubbink H, Atmodimedjo P, Kros J, French P, Sanson M, Idbaih A . Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol. 2015; 18(3):388-400. PMC: 4767239. DOI: 10.1093/neuonc/nov182. View